MCID: ADM013
MIFTS: 45

Adamantinoma of Long Bones

Categories: Eye diseases, Bone diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Adamantinoma of Long Bones

MalaCards integrated aliases for Adamantinoma of Long Bones:

Name: Adamantinoma of Long Bones 57 12 59 44
Long Bone Adamantinoma 12 15
Adamantinoma of Long Bone 12

Characteristics:

Orphanet epidemiological data:

59
adamantinoma of long bones
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
adamantinoma of long bones:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

OMIM 57 102660
Disease Ontology 12 DOID:2775
MeSH 44 C562741
Orphanet 59 ORPHA55881
ICD10 via Orphanet 34 C40.2
MESH via Orphanet 45 D050398
UMLS via Orphanet 74 C1367554
MedGen 42 C0334556
ICD10 33 H40-H42
UMLS 73 C0334556

Summaries for Adamantinoma of Long Bones

Disease Ontology : 12 An adamantinoma that is located in the long bones and results in focal epithelial differentiation.

MalaCards based summary : Adamantinoma of Long Bones, also known as long bone adamantinoma, is related to hepatocellular carcinoma and cholangiocarcinoma. An important gene associated with Adamantinoma of Long Bones is EGF (Epidermal Growth Factor). The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include Eye, the long bones and bone, and related phenotypes are bone pain and pathologic fracture

CDC : 3 Get Email Updates

Description from OMIM: 102660

Related Diseases for Adamantinoma of Long Bones

Diseases related to Adamantinoma of Long Bones via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 11.6 CCND1 H19 HULC MIR127 MIR141 MIR200A
2 cholangiocarcinoma 11.5 CCND1 EZH2 H19 HULC MIR141 MIR200B
3 gastric cancer 11.5 CCND1 H19 HULC MIR141 MIR200C NEAT1
4 breast cancer 11.5 CCND1 EZH2 H19 MIR127 MIR141 MIR200A
5 ovarian cancer 11.5 CCND1 H19 MIR141 MIR200A MIR200B MIR200C
6 prostate cancer 11.5 CCND1 EZH2 H19 HULC MIR127 MIR141
7 lung cancer 11.5 CCND1 H19 MIR141 MIR200A MIR200B MIR200C
8 bladder cancer 11.5 CCND1 EZH2 H19 HULC MIR127 PANDAR
9 melanoma 11.5 H19 MIR127 MIR141 MIR200A MIR200B MIR200C
10 cervical cancer 11.5 CCND1 H19 HULC NEAT1 NPTN-IT1 PANDAR
11 diffuse large b-cell lymphoma 11.5 EZH2 HULC MIR127 MIR17HG PANDAR
12 kidney cancer 11.5 H19 MIR141 MIR200B MIR200C
13 endometriosis 11.5 H19 MIR141 MIR200A MIR200B
14 osteogenic sarcoma 11.4 H19 HULC NEAT1 PANDAR PCAT1
15 renal cell carcinoma, nonpapillary 11.4 H19 MIR141 MIR200C NPTN-IT1 PANDAR
16 colorectal cancer 11.4 CCND1 H19 HULC MIR127 MIR141 MIR200C
17 osteofibrous dysplasia 11.4
18 oral squamous cell carcinoma 11.4 H19 MIR200B MIR200C NEAT1
19 thyroid cancer, nonmedullary, 1 11.4 H19 HULC MIR200A NEAT1
20 nasopharyngeal carcinoma 11.4 CCND1 H19 HULC NEAT1 NPTN-IT1
21 nonalcoholic fatty liver disease 11.3 MIR200B MIR200C MIR429
22 ovarian epithelial cancer 11.3 H19 HULC MIR127
23 squamous cell carcinoma, head and neck 11.3 CCND1 H19 MIR141 MIR200A
24 lung cancer susceptibility 3 11.3 CCND1 H19 MIR200B NPTN-IT1
25 glioma 11.3 CCND1 H19 HULC NEAT1
26 ovarian serous carcinoma 11.2 MIR141 MIR200A
27 prostate disease 11.2 H19 PCAT1
28 astrocytoma 11.2 H19 NBR2 NEAT1
29 mantle cell lymphoma 11.2 CCND1 EZH2 MIR17HG
30 squamous cell carcinoma 11.1 CCND1 H19 NEAT1 PCAT1
31 glioblastoma 11.1 CCND1 H19 MIR17HG PCAT1
32 tibial adamantinoma 11.0
33 pancreatic cancer 11.0 CCND1 H19 HULC MIR127 NEAT1
34 thyroid cancer 10.9 CCND1 H19 NEAT1 PANDAR
35 myeloma, multiple 10.6 CCND1 H19 PCAT1
36 fibrous dysplasia 9.9
37 ossifying fibroma 9.9

Graphical network of the top 20 diseases related to Adamantinoma of Long Bones:



Diseases related to Adamantinoma of Long Bones

Symptoms & Phenotypes for Adamantinoma of Long Bones

Symptoms via clinical synopsis from OMIM:

57
Oncology:
adamantinoma of long bones


Clinical features from OMIM:

102660

Human phenotypes related to Adamantinoma of Long Bones:

59 32
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 bone pain 59 32 frequent (33%) Frequent (79-30%) HP:0002653
2 pathologic fracture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002756
3 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
4 neoplasm 32 HP:0002664

Drugs & Therapeutics for Adamantinoma of Long Bones

Drugs for Adamantinoma of Long Bones (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
4 Anesthetics Phase 4
5 Anti-Inflammatory Agents Phase 4,Phase 1
6 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Not Applicable
7 Cortisol succinate Phase 4
8 glucocorticoids Phase 4,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Hydrocortisone 17-butyrate 21-propionate Phase 4
13 Hydrocortisone acetate Phase 4
14 Hydrocortisone-17-butyrate Phase 4
15
Diazoxide Approved Phase 3,Phase 2 364-98-7 3019
16
Exenatide Approved, Investigational Phase 3,Phase 2 141758-74-9 15991534
17 Antihypertensive Agents Phase 3,Phase 2
18 Vasodilator Agents Phase 3,Phase 2
19 Hypoglycemic Agents Phase 3,Phase 2
20 Incretins Phase 3,Phase 2
21 glucagon Phase 3
22 Glucagon-Like Peptide 1 Phase 3
23
Metformin Approved Phase 2 657-24-9 14219 4091
24
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
25
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
26
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
27
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
28
Memantine Approved, Investigational Phase 2 19982-08-2 4054
29
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
30
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
31
Camptothecin Experimental Phase 2 7689-03-4
32 insulin Phase 2
33 Insulin, Globin Zinc Phase 2
34 Antineoplastic Agents, Phytogenic Phase 2
35 topoisomerase I inhibitors Phase 2
36 Topoisomerase Inhibitors Phase 2
37 Anti-Infective Agents Phase 2,Phase 1
38 Protein Kinase Inhibitors Phase 2
39 Oxytocics Phase 2
40 Antiparkinson Agents Phase 2
41 Dopamine Agents Phase 2
42 Excitatory Amino Acid Antagonists Phase 2
43 Excitatory Amino Acids Phase 2
44 Neurotransmitter Agents Phase 2
45 Antiviral Agents Phase 2
46 Interferon-alpha Phase 2
47 interferons Phase 2
48 Fluorodeoxyglucose F18 Phase 2
49 Radiopharmaceuticals Phase 2,Not Applicable
50
Dacarbazine Approved, Investigational Phase 1 4342-03-4 5351166

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
4 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Recruiting NCT02860923 Phase 3 Exenatide;Placebo
5 Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed NCT00892073 Phase 2 Diazoxide;Metformin
6 An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
7 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Completed NCT01484873 Phase 2 Exenatide
8 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
9 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Recruiting NCT02367859 Phase 2 Dabrafenib;Trametinib
10 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
11 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
12 Intranasal Oxytocin in Hypothalamic Obesity Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
13 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Recruiting NCT03194906 Phase 2 Memantine
14 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
15 Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) Active, not recruiting NCT02842723 Phase 2
16 Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Active, not recruiting NCT01964300 Phase 2
17 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
18 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
19 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
20 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
21 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
22 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
23 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
24 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
25 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
26 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
27 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
28 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
29 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
30 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156
31 Social Participation After Childhood Craniopharyngioma Completed NCT03139526
32 1.5T Intraoperative MR Imaging in Craniopharyngiomas Completed NCT01206543 Not Applicable
33 Weight Gain in Surgically Treated Adult-onset Craniopharyngioma Completed NCT01968603
34 Sleep Wake and Melatonin Pattern in Craniopharyngioma Completed NCT01881854
35 Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma Completed NCT00258453 Not Applicable
36 Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients Recruiting NCT03330080
37 Prospective Study of Children and Adolescents With Craniopharyngioma Recruiting NCT01272622 Not Applicable
38 An Investigation of Pituitary Tumors and Related Hypothalmic Disorders Recruiting NCT00001595
39 Molecular-Guided Therapy for Childhood Cancer Recruiting NCT02162732 Not Applicable
40 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Active, not recruiting NCT00919750
41 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable

Search NIH Clinical Center for Adamantinoma of Long Bones

Cochrane evidence based reviews: adamantinoma of long bones

Genetic Tests for Adamantinoma of Long Bones

Anatomical Context for Adamantinoma of Long Bones

The Foundational Model of Anatomy Ontology organs/tissues related to Adamantinoma of Long Bones:

19
The Long Bones

MalaCards organs/tissues related to Adamantinoma of Long Bones:

41
Bone, Brain, Pituitary, T Cells, Spinal Cord, Eye, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Adamantinoma of Long Bones:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Ganglion Cell Layer Mature Ganglion Cells Affected by disease

Publications for Adamantinoma of Long Bones

Articles related to Adamantinoma of Long Bones:

(show all 21)
# Title Authors Year
1
Mesenchymal-epithelial differentiation of adamantinoma of long bones: an immunohistochemical and ultrastructural study. ( 22292734 )
2012
2
Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones. ( 21983933 )
2012
3
Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. ( 21499851 )
2011
4
Adamantinoma of long bones: a long-term follow-up study of 11 cases. ( 19048403 )
2009
5
MRI of adamantinoma of long bones in correlation with histopathology. ( 15547221 )
2004
6
Current trends in the management of adamantinoma of long bones. An international study. ( 10954102 )
2000
7
Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. ( 9582523 )
1998
8
Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation. ( 9023400 )
1997
9
Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia. ( 9242211 )
1997
10
DNA aberrations in the epithelial cell component of adamantinoma of long bones. ( 7495301 )
1995
11
Adamantinoma of long bones. A histopathological and immunohistochemical study of 23 cases. ( 7567680 )
1995
12
Test and teach. Number seventy-nine. Diagnosis: Adamantinoma of long bones. ( 7892039 )
1994
13
A clinicopathological and immunohistochemical study of osteofibrous dysplasia, differentiated adamantinoma, and adamantinoma of long bones. ( 1281557 )
1992
14
Adamantinoma of long bones. A clinicopathologic study of 85 cases. ( 2743266 )
1989
15
Unusual localization of adamantinoma of long bones. Report of a case of isolated fibular involvement. ( 3944167 )
1986
16
Adamantinoma of long bones. ( 6493828 )
1984
17
Adamantinoma of long bones: clinical, pathological and ultrastructural features. ( 7201477 )
1982
18
An unusual case of adamantinoma of long bones. ( 7161313 )
1982
19
Ultrastructure of adamantinoma of long bones. ( 6270877 )
1981
20
Ossifying fibroma of long bone: its distinction from fibrous dysplasia and its association with adamantinoma of long bone. ( 413432 )
1978
21
Adamantinoma of long bones. A clinicopathological study of fourteen cases with vascular origin suggested. ( 1112840 )
1975

Variations for Adamantinoma of Long Bones

Copy number variations for Adamantinoma of Long Bones from CNVD:

7 (show top 50) (show all 8840)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13322 1 1 124300000 Deletion Cancer
2 13338 1 1 124300000 Loss Cancer
3 13402 1 1 2300000 Gain or loss SKI Cancer
4 13748 1 1 27800000 Loss Cancer
5 13796 1 1 5160566 Amplification TP73 Cancer
6 13868 1 10029362 10546623 Deletion Cancer
7 13985 14 102200000 103000000 Deletion EIF5 Cancer
8 14318 1 10702796 10877203 Deletion Cancer
9 14336 1 107200000 111800000 Gain or loss VAV3 Cancer
10 14355 7 99902077 99914838 Amplification TSC22D4 Cancer
11 14359 7 99919485 99930358 Amplification C7orf51 Cancer
12 14363 1 107618378 107622430 Deletion Cancer
13 14406 1 107915304 108309068 Gain or loss VAV3 Cancer
14 14416 1 107928934 108839709 Insert NBPF4 Cancer
15 14417 1 107928934 108839709 Insert NBPF6 Cancer
16 14418 1 107928934 108839709 Insert SLC25A24 Cancer
17 14419 1 107928934 108839709 Insert VAV3 Cancer
18 14597 1 109594163 109619901 Gain or loss CELSR2 Cancer
19 14693 1 110000000 163800000 Gain Cancer
20 14795 1 110180814 110188022 Amplification or deletion RBM15 Cancer
21 14798 1 110230417 110260883 Deletion GSTM1 Cancer
22 14811 1 110339388 119426489 Deletion MAGI3 Cancer
23 14855 1 110683467 110690826 Gain or loss RBM15 Cancer
24 14882 1 11089178 11245151 Gain or loss FRAP1 Cancer
25 15022 1 111886577 112057624 Gain or loss RAP1A Cancer
26 15053 1 112169367 112371631 Insert KCND3 Cancer
27 15118 1 112811562 112865428 Gain or loss WNT2B Cancer
28 15156 1 113045271 113051548 Gain or loss RHOC Cancer
29 15168 1 113054138 113059473 Gain or loss PPM1J Cancer
30 15235 7 99974769 99991926 Amplification HRBL Cancer
31 15240 1 113734997 114030068 Gain or loss MAGI3 Cancer
32 15281 1 114238969 114352508 Amplification or deletion TRIM33 Cancer
33 15306 1 114548311 114558715 Amplification or deletion NRAS Cancer
34 15330 1 114736921 114855304 Gain or loss TRIM33 Cancer
35 15338 1 114736922 114855304 Amplification O75428 Cancer
36 15357 1 114911708 114925788 Amplification Q8TEE9 Cancer
37 15359 7 100009569 100021712 Amplification LRCH4 Cancer
38 15374 7 100021891 100036676 Amplification FBXO24 Cancer
39 15392 1 115048600 115061038 Gain or loss NRAS Cancer
40 15400 7 100037817 100043737 Amplification PCOLCE Cancer
41 15404 7 100047660 100050936 Amplification MOSPD3 Cancer
42 15409 7 100055974 100078338 Amplification TFR2 Cancer
43 15416 7 100078663 100091986 Amplification ACTL6B Cancer
44 15444 1 115630059 115682380 Gain or loss NGFB Cancer
45 15529 1 11657123 11674265 Gain or loss MAD2L2 Cancer
46 15602 7 100109310 100114728 Amplification GNB2 Cancer
47 15670 1 117922092 117959602 Deletion Cancer
48 15674 1 11796339 11809890 Deletion Cancer
49 15863 1 119996566 120303234 Amplification REG4 Cancer
50 15871 1 120065684 120415520 Insert ADAM30 Cancer

Expression for Adamantinoma of Long Bones

Search GEO for disease gene expression data for Adamantinoma of Long Bones.

Pathways for Adamantinoma of Long Bones

GO Terms for Adamantinoma of Long Bones

Sources for Adamantinoma of Long Bones

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....